CELLUMED CO., LTD.: debt-to-equity, ROE and more
KOSDAQ, Legal name CELLUMED CO., LTD.
Latest figures are the FY2025 consolidated summary statements.
Latest fiscal year ratios (computed here)
- Debt/equity
- 625.9%
- Equity ratio
- 13.8%
- ROE
- -26.0%
- Op. margin
- -3.7%
- Rev. growth
- 8.6%
- Interest coverage
- n/a
Condition flags
- Latest operating profit is not above zero, or not reported.
- Operating loss for 4 straight years.
- Total equity is below paid-in capital: partial impairment (자본잠식), rate 69.5%.
Interest coverage and dividends (OpenDART)
Interest expense and dividends come from DART's OpenDART annual-report filings, not the FSC summary statements used above. The source differs from the other tables on this page.
Interest coverage = operating profit ÷ interest expenseNo interest expense value yet for this company. Most companies fold interest expense into a single finance-costs line on their income statement, so it cannot be pulled out separately. Interest coverage is not computed here.
Dividends, last 3 fiscal years
No dividend data yet for this company.
Source values from the OpenDART (금융감독원 전자공시) annual report. Report fiscal year 2025.
Ratios by year (computed here)
Debt-to-equity = total liabilities ÷ total equity × 100Equity ratio = total equity ÷ total assets × 100ROE = net income ÷ year-end total equity × 100Operating margin = operating profit ÷ revenue × 100Revenue growth = (this year − last year) ÷ last year × 100
Computed from the source figures above with these formulas. Where the source's own debt-to-equity differs from ours, both are shown for that year.
| Fiscal year | Debt/equity | Equity ratio | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| FY2021 consolidated | 96.5% | 50.9% | 17.2% | 4.7% | n/a |
| FY2022 consolidated | 69.2% | 59.1% | -9.8% | -2.2% | 22.2% |
| FY2023 consolidated | 188.8% | 34.6% | -164.8% | -10.9% | -21.7% |
| FY2024 consolidated | 675.0% | 12.9% | -351.1% | -5.3% | 35.1% |
| FY2025 consolidated | 625.9% | 13.8% | -26.0% | -3.7% | 8.6% |
Source figures (FSC summary statements)
Amounts are the source values, shortened. A cell reported as zero may be blank in the source, so it is not used in any ratio.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | ₩99.9B | ₩122.1B | ₩95.6B | ₩129.1B | ₩140.2B |
| Operating profit | ₩4.7B | -₩2.7B | -₩10.5B | -₩6.8B | -₩5.1B |
| Pre-tax income | ₩9.1B | -₩4.8B | -₩38.6B | -₩32.1B | -₩2.2B |
| Net income | ₩8.4B | -₩5.4B | -₩37.9B | -₩31.8B | -₩2.2B |
| Total assets | ₩96.4B | ₩93.3B | ₩66.5B | ₩70.2B | ₩60.9B |
| Total liabilities | ₩47.3B | ₩38.1B | ₩43.5B | ₩61.2B | ₩52.5B |
| Total equity | ₩49.1B | ₩55.1B | ₩23.0B | ₩9.1B | ₩8.4B |
| Paid-in capital | ₩19.8B | ₩20.9B | ₩21.4B | ₩25.8B | ₩27.5B |
| Debt/equity (source value) | 96.5% | 69.2% | 188.8% | 675.0% | 625.9% |
Company outline (FSC)
- Market
- KOSDAQ
- Fiscal year end
- Dec
- Founded
- 1985-04-30
- Listed
- 02/05/23
- Employees
- 83
- Auditor
- 이정회계법인
- Audit opinion
- 의견거절
- Corporate reg. no.
- 1201110019225
- Outline updated
- 2026-09-24
Check the original filings
Read the annual report and audit report before you decide anything. The link opens a DART search for this company's name.
Search DART for 셀루메드Computed from the Financial Services Commission's company outline and summary statements (data.go.kr). Data as of 2026-09-24.